Abbott To Buy Solvay's Pharma Unit For $6.6B Cash
The Illinois-based drugmaker said Monday that the acquisition would add more than $3 billion in annual sales and position it in high-growth markets in Eastern Europe and Asia. It will also add about $500 million a year for pharmaceutical research and development investment, the company said.
“In anticipation of future market needs, we...
To view the full article, register now.